# Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.

> **NCT07655661** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ming Liu** · enrollment: 52 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Tislelizumab
- **DRUG:** Mannatide

## Key facts

- **NCT ID:** NCT07655661
- **Lead sponsor:** Ming Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07655661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07655661, "Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07655661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*